A Phase II Study on Everolimus, an mTOR Inhibitor (Oral Formulation), With Octreotide LAR (RM) in Adult Patients With Advanced, Non-functioning, Well-differentiated Gastrointestinal Neuroendocrine Tumours (GI NET)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Octreotide
Indications Gastrointestinal cancer; Neuroendocrine tumours
Focus Therapeutic Use
Acronyms EVERLAR

Most Recent Events

02 Jan 2018 Status changed from active, no longer recruiting to completed.
29 May 2017 Planned End Date changed from 1 Apr 2018 to 7 Jun 2017.
11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight